DRD2 and neoplasm: Hoeppner et al. demonstrated that D2R agonists (Cabergoline) inhibited NSCLC tumor progression in orthotopic lung tumor models through two mechanisms: a reduction in tumor angiogenesis in lung endothelial cells and abrogation of tumor-infiltrating MDSCs [100].